<DOC>
	<DOCNO>NCT03029338</DOCNO>
	<brief_summary>In single-center , open-label , control , prospective clinical trial , total 10 relapse refractory CD19 positive B-cell Non-Hodgkin Lymphoma ( NHL ) patient enrolled.CD19 CAR T cell ( total dose 2×10^6/kg-1×10^7/kg ) intravenously infused patient three-day split-dose regimen : 10 % day 0 , 30 % day 1 60 % day 2 . The purpose current study determine clinical efficacy safety CD19 CAR T cell patient relapse refractory CD19 positive B-cell lymphoma .</brief_summary>
	<brief_title>CD19 CAR T Cells Patients With Relapsed Refractory CD19 Positive B-cell Lymphoma</brief_title>
	<detailed_description>In single-center , open-label , nonrandomized , control , prospective clinical trial , total 10 relapse refractory CD19+ B-cell Non-Hodgkin Lymphoma ( NHL ) patient enrol . CD19 CAR T cell transduce lentiviral vector express anti-CD19 scFv TCRζ:4-1BB , administer i.v . injection three-day split-dose regimen : 10 % day 0 , 30 % day 1 60 % day 2 . Side effect CD19 CAR T cell therapy monitor . The purpose current study determine clinical efficacy safety CD19 CAR T cell therapy patient relapse refractory CD19 positive B-cell lymphoma .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<criteria>Patients age 18 70 year relapse refractory CD19 positive Bcell lymphoma . Eastern Cooperative Oncology Group ( ECOG ) Performance status 02 . Adequate end organ function define : Total bilirubin ≤ 1.5 x upper limit normal（ULN） ; Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 2.5 x ULN ; Creatinine ≤ 1.5 x ULN serum creatinine level associate measure calculated creatinine clearance ≥ 40ml/min . Male female reproductive potential must agree use birth control study least 6 week post study . Patients sign inform consent form . Patients central nervous system involvement lymphoma . Prior chemotherapy within 2 week enrollment follow exception : steroid , hydroxyurea , oral mercaptopurine , methotrexate , vincristine thioguanine permit within 2 week enrollment maintenance reduce tumor load . Prior allogeneic hematopoietic stem cell transplant ( HSCT ) ≤ 4 month enrollment . Patients must complete immunosuppression therapy prior enrollment . At enrollment , patient must have≥ grade 2 acute GVHD , either moderate severe limited chronic GVHD , extensive GVHD severity . Known systemic vasculitides , primary secondary immunodeficiency ( HIV infection severe inflammatory disease ) . Major surgery within 4 week enrollment . Impaired cardiac function : Ejection fraction ≤45 % MUGA scan . QTc interval &gt; 450msecs baseline ECG . Myocardial infarction within 6 month prior start study ; clinically significant heart disease ( e.g . unstable angina , congestive heart failure uncontrolled hypertension , uncontrolled arrhythmia ) . Administration live vaccine ≤ 4 week enrollment . Other concurrent severe and/or uncontrolled medical condition : Patients another primary malignant disease , except currently require treatment ; acute chronic liver , pancreatic severe renal disease ; another severe and/or lifethreatening medical disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>lymphoma</keyword>
	<keyword>non-hodgkin</keyword>
	<keyword>B-cell</keyword>
	<keyword>CD19 CAR T cell</keyword>
	<keyword>refractory</keyword>
	<keyword>relapse</keyword>
</DOC>